Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 299

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 299
---
 grant received by the Company, linked to U.S. dollar and bearing Term SOFR interest rate. In the case of failure of a funded 
 research and development activity, the Company is not obligated to pay any such royalties to the IIA. As of June 30, 2025, total    
 contingent obligation to IIA is approximately $2,685 (including interest at approximately the amount of $340).                      |

<div align='center'>F-44</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 7:- | COMMITMENTS AND CONTINGENCIES (Cont.) |

| 2. | In February 2018, the                                                                                                                
 Company entered into a services agreement with Baxter Healthcare Corporation (the “Baxter Services Agreement” and “Baxter”,          
 respectively), pursuant to which the Company agreed to purchase certain services from Teva Medical (Marketing) Ltd. (“Teva”)         
 in connection with GelrinC. In April 2022, we amended the Baxter Services Agreement to replace Teva as the supplier of Tisseel under 
 the Supply Agreement for GelrinC with Baxter as Teva ceased to distribute Tisseel in Israel.                                         |

Under the Baxter Services Agreement,
Baxter provides the Company with quality, regulatory and technical support, for up to a maximum aggregate of 40 man-hours per year for
all such support. In consideration for receiving such support, the Company pays Baxter $60 per year until the Company received Food and
Drug Administration (the “FDA”) approval to market GelrinC in the United States. Following FDA approval to market GelrinC
in the United States, the Company will pay Baxter $200 per year during the term of this Services Agreement; however, the year the Company
will receive an FDA approval to market GelrinC in the United States, the Company must pay the remining $140 balance for that year within
30 days after receiving such approval. The Company incurred expenses under the Services Agreement of $30 in each of the six months ended
June 30, 2025 and 2024.

| 3. | In July 2008, the Company                                                                                                                 
 entered into a Supply Agreement with Baxter and Teva which was amended and restated on January 6, 2009, pursuant to which the Company     
 agreed to purchase Tisseel VHSD